Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yves Aubin

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Infectious Diseases of Poverty|April 28, 2022
High infection rates for onchocerciasis and soil-transmitted helminthiasis in children under five not receiving preventive chemotherapy: a bottleneck to eliminationHugues C Nana-Djeunga, Linda Djune-Yemeli, André Domche, et al.
Journal of Pharmaceutical and Biomedical Analysis|January 15, 2019
Survey of peptide quantification methods and comparison of their reproducibility: A case study using oxytocinChensheng Li, Sitaram Bhavaraju, Marie-Pier Thibeault, et al.
Open Forum Infectious Diseases|July 5, 2024
Safety and Short-term Efficacy of a Single Dose of 2 mg Moxidectin in <i>Loa loa</i>-Infected Individuals: A Double-Blind, Randomized Ivermectin-Controlled Trial With Ascending Microfilarial DensitiesGuy S Wafeu, Tristan M Lepage, Jeremy T Campillo, et al.
Journal of Medicinal Chemistry|February 16, 2007
Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524)Claudio F Sturino, Gary O'Neill, Nicolas Lachance, et al.
Mabs|December 21, 2018
Enabling adoption of 2D-NMR for the higher order structure assessment of monoclonal antibody therapeuticsRobert G Brinson, John P Marino, Frank Delaglio, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Infectious Diseases of Poverty|April 28, 2022
High infection rates for onchocerciasis and soil-transmitted helminthiasis in children under five not receiving preventive chemotherapy: a bottleneck to eliminationHugues C Nana-Djeunga, Linda Djune-Yemeli, André Domche, et al.
Journal of Pharmaceutical and Biomedical Analysis|January 15, 2019
Survey of peptide quantification methods and comparison of their reproducibility: A case study using oxytocinChensheng Li, Sitaram Bhavaraju, Marie-Pier Thibeault, et al.
Open Forum Infectious Diseases|July 5, 2024
Safety and Short-term Efficacy of a Single Dose of 2 mg Moxidectin in <i>Loa loa</i>-Infected Individuals: A Double-Blind, Randomized Ivermectin-Controlled Trial With Ascending Microfilarial DensitiesGuy S Wafeu, Tristan M Lepage, Jeremy T Campillo, et al.
Journal of Medicinal Chemistry|February 16, 2007
Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524)Claudio F Sturino, Gary O'Neill, Nicolas Lachance, et al.
Mabs|December 21, 2018
Enabling adoption of 2D-NMR for the higher order structure assessment of monoclonal antibody therapeuticsRobert G Brinson, John P Marino, Frank Delaglio, et al.
Pageof 4